Based on the recent data, the treatment success rate for patients treated for multidrug-resistant tuberculosis in China has shown a slow upward trend. In 2023, this rate was at 56%. The forecast suggests a modest increase: maintaining at 57% for 2024 and 2025, rising to 58% in 2026 and 2027, and reaching 59% by 2028. The annual growth is gradual, with the compound annual growth rate over five years being modest. With this steady trend, it indicates a slow yet positive movement towards better treatment outcomes.

In terms of future trends, it's essential to monitor:

New treatment protocols or drugs that may accelerate success rates.
Government and healthcare initiatives improving accessibility and effectiveness of treatments.
Cross-sector collaboration to address drug resistance comprehensively.